Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12001744 | 0.77 | PAK4 (0.39) | MAP3K14ALDH1A1PDE4BPDE4D | |
| SCHEMBL11970447 | 0.77 | MAP3K14 (0.45) | MAP3K14CDC7CDK2ROCK1NPC1 | |
| SCHEMBL11970613 | 0.75 | MAP3K14 (0.72) | MAP3K14CDC7CDK2ROCK1 | |
| SCHEMBL11971090 | 0.74 | PAK4 (0.58) | MAP3K14 | |
| SCHEMBL11970783 | 0.74 | MAP3K14 (0.50) | MAP3K14CDC7CDK2ROCK1 | |
| SCHEMBL12490103 | 0.74 | MAP3K14 (0.43) | MAP3K14CDC7CDK2ROCK1DYRK1A | |
| SCHEMBL11970770 | 0.73 | MAP3K14 (0.43) | MAP3K14CDC7CDK2ROCK1NPC1 | |
| SCHEMBL11970914 | 0.72 | MAP3K14 (0.51) | MAP3K14CDC7CDK2ROCK1 | |
| SCHEMBL12490171 | 0.72 | MAP3K14 (0.43) | MAP3K14 | |
| SCHEMBL11970511 | 0.71 | MAP3K14 (0.50) | MAP3K14CDC7CDK2ROCK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2014170421-A1 | SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014170421-A1 | SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | WO | disclosed |
| EP-2686314-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012123522-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123522-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | MAP3K14 519/4885CDC7 4283/4885CDK2 2025/4885 |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | NFKB1, NFRKB, NFKBIA | MAP3K14 519/4885CDC7 4283/4885CDK2 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.